Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.31 -1.9%	$8.70	$6.01 ▼ $11.31	$1.74B	1.1	3.74 million shs	2.31 million shs
CLDX Celldex Therapeutics	$22.08 -1.3%	$22.29	$14.40 ▼ $47.00	$1.47B	1.22	1.00 million shs	1.33 million shs
FOLD Amicus Therapeutics	$7.59 -0.8%	$6.49	$5.51 ▼ $12.65	$2.34B	0.53	3.86 million shs	4.15 million shs
RIGL Rigel Pharmaceuticals	$38.85 -1.2%	$25.77	$12.66 ▼ $43.72	$696.85M	1.21	315,019 shs	846,456 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-0.59%	+1.07%	+4.70%	-21.06%	-0.94%
CLDX Celldex Therapeutics	-0.97%	+1.63%	+1.96%	+14.83%	-41.82%
FOLD Amicus Therapeutics	+0.13%	+0.66%	+24.80%	+25.20%	-31.76%
RIGL Rigel Pharmaceuticals	-1.06%	-6.38%	+97.54%	+103.68%	+204.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.2503 of 5 stars	3.5	2.0	4.2	3.1	2.5	0.6
CLDX Celldex Therapeutics	1.8 of 5 stars	3.4	3.0	0.0	2.8	0.0	0.0
FOLD Amicus Therapeutics	4.3051 of 5 stars	3.4	2.0	4.3	3.5	0.0	1.9
RIGL Rigel Pharmaceuticals	1.5858 of 5 stars	1.2	1.0	0.0	2.6	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	100.96% Upside
CLDX Celldex Therapeutics	2.78	Moderate Buy	$46.67	111.35% Upside
FOLD Amicus Therapeutics	2.80	Moderate Buy	$16.22	113.73% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	-1.67% Downside

Current Analyst Ratings Breakdown

Latest RIGL, FOLD, BCRX, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$44.00 ➝ $38.00
8/20/2025	CLDX Celldex Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$56.00 ➝ $48.00
8/20/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $62.00
8/20/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $42.00
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
8/4/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/17/2025	FOLD Amicus Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	3.87	N/A	N/A	($2.01) per share	-4.13
CLDX Celldex Therapeutics	$5.79M	253.24	N/A	N/A	$9.87 per share	2.24
FOLD Amicus Therapeutics	$528.29M	4.43	N/A	N/A	$0.66 per share	11.50
RIGL Rigel Pharmaceuticals	$267.92M	2.60	$1.05 per share	36.83	$4.57 per share	8.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.18	N/A	N/A	1.94	-6.41%	N/A	-1.78%	11/3/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$3.01	N/A	N/A	N/A	-3,446.88%	-27.61%	-26.20%	11/5/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.12	N/A	17.65	N/A	-6.67%	-5.07%	-1.23%	11/5/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	7.18	37.00	N/A	36.51%	438.89%	57.03%	11/6/2025 (Estimated)

Latest RIGL, FOLD, BCRX, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	-$0.85	+$0.01	-$0.85	$1.13 million	$0.73 million
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.03	$0.15	+$0.12	$0.02	$149.59 million	$163.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.25	2.22
CLDX Celldex Therapeutics	N/A	19.67	19.67
FOLD Amicus Therapeutics	1.92	3.21	2.29
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CLDX Celldex Therapeutics	N/A
FOLD Amicus Therapeutics	N/A
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	5.10%
CLDX Celldex Therapeutics	4.40%
FOLD Amicus Therapeutics	2.20%
RIGL Rigel Pharmaceuticals	9.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.92 million	199.21 million	Optionable
CLDX Celldex Therapeutics	150	66.41 million	63.49 million	Optionable
FOLD Amicus Therapeutics	480	308.24 million	301.46 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable

RIGL, FOLD, BCRX, and CLDX Headlines

Recent News About These Companies

Rigel to Participate in Upcoming September Investor Conferences

August 26 at 8:05 AM | prnewswire.com

This ‘Darling’ Pharma Stock Is Hitting New Highs, But the Momentum Could Run Out Soon

August 25, 2025 | finance.yahoo.com

This ‘Darling’ Pharma Stock Is Hitting New Highs

August 25, 2025 | barchart.com

Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?

August 25, 2025 | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Reaches New 1-Year High - What's Next?

August 21, 2025 | marketbeat.com

Head-To-Head Analysis: Rigel Pharmaceuticals (NASDAQ:RIGL) vs. Lipocine (NASDAQ:LPCN)

August 21, 2025 | americanbankingnews.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Sees Strong Trading Volume - Should You Buy?

August 20, 2025 | marketbeat.com

Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) PT at $38.20

August 19, 2025 | americanbankingnews.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Recommendation of "Hold" from Brokerages

August 17, 2025 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Up 3.3% - Should You Buy?

August 16, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Increases Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

August 16, 2025 | marketbeat.com

Overlooked Stock: RIGL Nearly Doubles Stock in August

August 15, 2025 | youtube.comY

Rigel Pharmaceuticals (NASDAQ:RIGL) Sets New 12-Month High - Time to Buy?

August 14, 2025 | marketbeat.com

Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

August 13, 2025 | seekingalpha.com

Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are Of Questionable Quality

August 13, 2025 | finance.yahoo.com

H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT

August 12, 2025 | finance.yahoo.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Sees Unusually-High Trading Volume - Time to Buy?

August 10, 2025 | marketbeat.com

RIGL FY2025 EPS Forecast Increased by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Estimate for RIGL Earnings

August 9, 2025 | marketbeat.com

Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?

August 8, 2025 | zacks.com

Best Momentum Stock to Buy for August 8th

August 8, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL, FOLD, BCRX, and CLDX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.31 -0.16 (-1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$8.35 +0.04 (+0.42%)

As of 07:05 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics NASDAQ:CLDX

$22.08 -0.30 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$22.08 0.00 (0.00%)

As of 06:08 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Amicus Therapeutics NASDAQ:FOLD

$7.59 -0.06 (-0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$7.58 0.00 (-0.07%)

As of 05:38 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Rigel Pharmaceuticals NASDAQ:RIGL

$38.85 -0.46 (-1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$38.52 -0.33 (-0.85%)

As of 07:41 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time